Pharmaceutical Sector

Raritan recalls homeopathic products due to potentially poisonous ingredient

Raritan recalls homeopathic products due to potentially poisonous ingredient

Raritan Pharmaceuticals Inc. has issued a voluntary recall for multiple homeopathic products over uncertainty about the amount of potentially toxic belladonna extract, according to a MedWatch alert by the U. S. Food & Drug Administration (FDA).

A number of homeopathic products for kids contain belladonna in very small amount. In spite of carrying the Italian term for "beautiful lady," belladonna can cause serious side effect and harm if consumed in larger doses. For instance, it can block functions of the body's nervous system.

Companies: 
General: 

Nick Cannon criticizes Planned Parenthood

Nick Cannon criticizes Planned Parenthood

American rapper & actor Nick Cannon, one of the most outspoken celebrities, has criticized the controversial Planned Parenthood program, saying it is committing 'genocide' against the black community.

Cannon, known for his outspoken nature, spoke against Planned Parenthood while chatting with the Breakfast Club late last week. His comments against the federal program left many people surprised because he never showed support for Republican president-elect Donald Trump who repeatedly attacked the program during his election campaign.

Companies: 

Alnylam stock plunges after company announced end of experimental drug

Alnylam stock plunges after company announced end of experimental drug

Stock in Alnylam Pharmaceuticals Inc. nosedived late Wednesday after the company announced its decision to end development of its late-stage experimental drug for a rare disease due to safety concerns.

The drug in question, dubbed revusiran, was being developed by Alnylam for treating a condition called hereditary amyloidosis with cardiomyopathy, in which amyloid plaque accumulates in organs like heart, where it can cause heart attack.

General: 

European Medicines Agency to review Samsung Bioepis’s Application of Humira biosimilar

European Medicines Agency to review Samsung Bioepis’s Application of Humira bios

On Monday, Samsung Bioepis, devoted to create affordable and high-quality biopharmaceutical and biosimilar products said is seeking regulatory approval in Europe to sell Humira, its copy of AbbVie Inc's rheumatoid arthritis drug.

Companies: 
General: 
Region: 

Martin Shkreli Pleads not Guilty to New Charge brought Against Him

Martin Shkreli

A new charge was brought against Martin Shkreli, the Pharma industry entrepreneur accused of defrauding potential investors. On Monday, he pleaded not guilty to the updated indictment which brought a new conspiracy charge. He also jeered at the federal prosecutors.

Region: 
General: 

Does Fewer Opioid Prescriptions in the U.S Reflect a Curb in the Wave of Addiction

Does Fewer Opioid Prescriptions in the U.S Reflect a Curb in the Wave of Addicti

On Friday, a data released by The New York Times revealed that in almost two decades for the very first time there has been a drop in the number of opioid prescriptions in the U.S.  

The opioid drugs have been found to be highly addictive. The data is based on the findings of a new body of research by IMS Health. Last year almost seventeen million lesser number of opioid prescriptions was filled. This decline in prescription for the pain-relieving medications signals at a shift in medical practices but at the same time increases a need to look for alternatives.

General: 

Pfizer planning to acquire Anacor Pharmaceuticals

Pfizer planning to acquire Anacor Pharmaceuticals

Pharmaceutical giant, Pfizer Inc has entered into adefinitive merger agreementwith Anacor Pharmaceuticals.

Companies: 
General: 

Pfizer to restrict use of its products in lethal injections

Pfizer to restrict use of its products in lethal injections

Second largest pharmaceutical company in the world, Pfizer has strengthened its control on the distribution channels in order to ensure that any of its products are not used in lethal injections.

Companies: 
General: 

Abbott Laboratories Acquiring Medical Technology and Service Company St. Jude for $25 Billion

Abbott Laboratories Acquiring Medical Technology and Service Company St. Jude fo

On Thursday, Abbott Laboratories said it would buy Minnesota based, medical technology company St. Jude Medical Inc for $25 billion. Te main aim is to enlarge its heart device business. However, investors are worried that this acquisition will most probably not pay off like it's promised. It will be a cash-and-stock acquisition. Abbott plans to borrow money for the deal.

General: 

Michael Pearson, Valeant’s Outgoing CEO Admits Dramatic Increases of Certain Drugs was a Mistake

Michael Pearson, Valeant’s Outgoing CEO Admits Dramatic Increases of Certain Dru

On Wednesday, Valeant Pharmaceuticals International Inc's outgoing CEO Mr. Pearson told a Senate committee that the company was too aggressive in radically raising its drug prices and it was a mistake. The company's new CEO and the board members promise that a change will be noticed soon.

Companies: 
General: 

Pages